Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford are investigating the long-term health outcomes for patients who have been treated for severe COVID-19 disease in intensive care.

Image of a calendar © Photo by Eric Rothermel on Unsplash

To date, over 12,000 patients have been treated on an Intensive Care Unit (ICU) in England, Wales and Northern Ireland for very severe COVID-19 disease. Around 60% of them have survived to leave hospital, after an average of 11 days of care. Scientists are not only unclear on the long-term effects of the disease itself; they also know very little about the impact of a stay in ICU on these patients.

Before the COVID-19 outbreak, the Oxford Critical Care Research Group (CCRG) had developed efficient approaches to systematically follow up ICU patients over the long term. Their approach involves linking data from the Case Mix Programme, to which ICUs report, to multiple other routine healthcare data sources, through NHS Digital.

This new study funded by The University of Oxford's COVID-19 Research Response Fund will look at key six-month health outcomes in patients who survived severe COVID-19 in England. It will provide timely data on additional risks faced by survivors that might be mitigated by specialist or community follow-up.

Stephen Gerry, Senior Medical Statistician at NDORMS commented: "Understandably, due to the incredibly large numbers of people affected, more attention is being given to the long term prospects of patients who have had severe COVID-19. This is an exciting project, because uniquely we will be able to follow all patients who have been discharged from ICUs in England, Wales, or NI, having recovered from COVID-19. It is a great opportunity to gain a clear understanding of what will happen to these patients, and we hope that our research will help inform clinical practice."

It is hoped that this initial study will lead to further research on longer-term follow-up, with a wider range of patient outcomes.

Similar stories

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.

New research could improve quality of life for Psoriatic Arthritis patients

Professors Laura Coates and Dani Prieto-Alhambra will take major roles in a new European Commission project to develop innovative personalised treatment options for people affected by psoriatic arthritis.